Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MC2 TCR T cells in MAGE-C2+ Melanoma and HNSCC
NCT04729543Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2020
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MP71-MC2-TCR16-3D9 in melanoma, head and neck squamous cell carcinoma (HNSCC), sponsored by Erasmus MC. Started Oct 2020; status: recruiting.
02
Drugs
MP71-MC2-TCR16-3D9
03
Conditions
melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04729543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729543.